A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

To be considered for this study, you need a confirmed diagnosis of COPD from your doctor. You must be a current or past smoker with a history of smoking for at least 10 years, and your COPD should be considered moderate to severe. Your breathing difficulties should also be significant enough to affect your daily life.

Drs are also looking for specific signs of inflammation in your blood called 'Type 2 inflammation,' which is measured by certain blood cells (eosinophils). Your current COPD treatment should include a combination of three types of medicines for at least three months, or two if one is not suitable for you. You cannot have asthma or other major lung diseases, such as lung scarring or severe high blood pressure in the lungs. You also can't be on very high levels of oxygen at home or have had a lung infection recently.

You also won't be able to join if you're already taking certain biological treatments for your lung condition, including any experimental drugs or dupilumab. If you take medicines to thin mucus, you need to have been on a stable dose for more than six months. The study is very specific about who can take part to ensure safety and that the results are as clear as possible.

If you decide to take part in this study, you would visit the clinic 9 times over a maximum period of 40 weeks, which is about 9-10 months. The actual study medication (either dupilumab or a dummy treatment) would be given to you for up to 24 weeks, which is about 5-6 months. During your visits, doctors and nurses would perform various checks, which might include breathing tests, blood samples, and symptom questionnaires. You would receive the study medication regularly, likely by injection under the skin, as directed by the study team. You would also continue your regular COPD medications unless advised otherwise by the study doctor.